N C Med J. 2008 May-Jun;69(3):188-94.N C Med J. 2008.PMID: 18751350Free PMC article..
.
.
Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
Anderson TS, Ayanian JZ, Souza J, Landon BE..
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators.. Careau V, et al.Curr Biol. 2021 Aug 26:S0960-9822(21)01120-9. doi: 10.1016/j.cub.2021.08.016. Online ahead of print.Curr Biol. 2021.PMID: 34453886.
. Deepak P, et al.Ann Intern Med. 2021 Aug 31:M21-1757. doi: 10.7326/M21-1757. Online ahead of print.Ann Intern Med. 2021.PMID: 34461029.